Decision Diagnostics (OTC: DECN) CEO Keith Berman discusses the company’s products targeting the $25 billion global diabetes monitoring market, and the company’s path to achieving $100 million+ revenues within next 2 years.
Topics discussed include:
- DECN’s products which offer competitive advantages including greater accuracy, and cost saving of about 50%.
- New product pipeline, including a “game changer” launching in 2019
- FDA filings update
- Update on JNJ litigation
- Veterinary products update
- And More
Investor Fact Sheet
Decision Diagnostics